Dr Amol Akhade
@suyogcancer
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists
ID: 1135941148378247168
http://suyogcancerclincs.com 04-06-2019 16:07:29
6,6K Tweet
3,3K Followers
125 Following
Does covid-19 still has same impact in your country as it was during 2020-21 ? Do u think covid-19 is something to worry of beyond usual viral fever with cough and cold ? Does this vaccine still needs emergency use authorisation? My answer - NO for all 3 Vinay Prasad MD MPH
Tissue agnostic approvals from 2017 till now ESMO - Eur. Oncology . Lets see the Other side of the coin. 1 - It is great to have Tissue Agnostic approvals and works well for NTRK fusion, B-RAF mutation and RET fusion and to some extent for MSI high . But for HER2-3 plus and TMB high
Esmo presidential sessions ESMO - Eur. Oncology #ESMO24 What is the exciting data to look forward to - My Take 1 - OS data for Keynote- 522 - pembrolizumab for Neoadjuvant TNBC. 2- NIAGARA - neoadjuvant Durvalumab plus chemo followed by sx and adjuvant Durvalumab for MIBC . 3 - OS data
oncologynewscentral.com/article/fda-opโฆ Hello everyone, Do read my Opinon piece published on oncology news central Oncology News Central, about recent USFDA approval of blood based colon cancer screening test . Do give your feedback and opinions ๐ LARVOL Cancer Data etc OncoAlert FDA Oncology
Dr Amol Akhade Oncology News Central LARVOL Cancer Data etc OncoAlert FDA Oncology We would like to inform you that your post has been successfully published on @Oncodaily. Thank you for sharing! oncodaily.com/blog/132619
Whats new data coming up at ESMO - Eur. Oncology #esmo24 in lung cancer ? What's coming up for Lung Cancer In ESMO 24 ? My Take Phase 3 data - 1- adjuvant durvalumab alone in completely resected NSCLC 2- second interim OS from Mariposa-2 trial 3 - low dose vs standard dose
Dr.Dr Amol Akhade about FDA Oncology approval of blood based colon cancer screening test Oncology News Central oncodaily.com/blog/132619 #Cancer #BloodCancer #OncEd #CancerScreening #OncoDaily #Oncology
In Clinical Oncology, Dr Mark Lythgoe and I comment on the state of supportive care in oncology. Metrics including drug approvals, global funding, and the number of ongoing clinical trials show a predominant focus on anti-cancer therapeutics over supportive care interventions.
Dr Amol Akhade Interesting blog on the HARMONI-2 backstory ๐The Wild West of World Lung Cancer #WCLC24 kolpulse.com/uptempo-blog/tโฆ